| Identification | More | [Name]
Lornoxicam | [CAS]
70374-39-9 | [Synonyms]
6-CHLORO-4-HYDROXY-2-METHYL-N-2-PYRIDINYL-2H-THIENO[2,3-E]-1,2-THIAZINE-3-CARBOXAMIDE 1,1-DIOXIDE
AKOS 93662
LORNOXICAM
2h-thieno(2,3-e)-1,2-thiazine-3-carboxamide,6-chloro-4-hydroxy-2-methyl-n-2-py
chlortenoxicam
ridinyl-,1,1-dioxide
6-Chloro-4-hydroxy-2-methyl-N-pyridin-2-yl-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide-1,1-dioxide
LornoxicamConsultedStandard
Ro 13-9297
Telos
TS 110
Xefo
Xefocam
6-Chloro-4-hydroxy-2-methyl-N-pyridin-2-yl-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide (Lornoxicam)
6-Chloro-4-hydroxy-2-methyl-N-2-pyridinyl-2H-thieno[2,3-e]-1，2-thiazine-3-carboxamidel，1-dioxide
6-Chloro-4-hydroxy-2-methyl-N-(2-pyridyl)-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide | [EINECS(EC#)]
630-354-7 | [Molecular Formula]
C13H10ClN3O4S2 | [MDL Number]
MFCD00866163 | [Molecular Weight]
371.82 | [MOL File]
70374-39-9.mol |
| Chemical Properties | Back Directory | [Appearance]
Crystalline Solid | [Melting point ]
225-230°C (dec.) | [density ]
1.742±0.06 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Inert atmosphere,Store in freezer, under -20°C | [solubility ]
DMSO: >5mg/mL (warmed) | [form ]
powder | [pka]
pKa2 4.7(at 25℃) | [color ]
faint yellow to dark yellow | [Usage]
Cyclooxygenase inhibitor; structurally similar to tenoxicam. Anti-inflammatory; analgesic | [Merck ]
14,5582 | [InChIKey]
WLHQHAUOOXYABV-UHFFFAOYSA-N | [CAS DataBase Reference]
70374-39-9(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
Xi | [Risk Statements ]
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36:Wear suitable protective clothing . | [RIDADR ]
UN 2811 6.1 / PGII | [WGK Germany ]
3 | [RTECS ]
XJ9095000 | [HazardClass ]
IRRITANT | [PackingGroup ]
II | [HS Code ]
29349990 | [Toxicity]
LD50 orally in mice, rats, rabbits, dogs, monkeys: >10 mg/kg (Pruss) |
| Questions And Answer | Back Directory | [Description]
Lornoxicam (Trade name: “Xefo”) belongs to a non-steroidal anti-inflammatory drug. As a kind of oxicam class drug, it has analgesic, anti-inflammatory and antipyretic properties. It can be used for the treatment of various type of acute mild to moderate pain which results from inflammatory diseases of the joints, osteoarthritis, surgery, sciatica and rheumatic diseases. Lornoxicam is capable of potently inhibiting the prostaglandin biosynthesis process, making it have highly pronounced efficacy. The exact mechanism of Lornoxicam is not exactly understood. However, it is indicated that Lornoxicam can inhibit the prostaglandin and thromboxane synthesis by inhibiting both COX-1 and COX-2, leading to reduction of inflammation, pain, fever, and swelling.
| [References]
https://www.drugbank.ca/drugs/DB06725
https://en.wikipedia.org/wiki/Lornoxicam
|
| Hazard Information | Back Directory | [Chemical Properties]
Crystalline Solid | [Originator]
Nycomed Amersham (Norway) | [Uses]
Cyclooxygenase inhibitor; structurally similar to tenoxicam. Anti-inflammatory; analgesic | [Uses]
For the treatment of acute mild to moderate pain, as well as pain and inflammation of the joints caused by certain types of rheumatic diseases. | [Uses]
keratolytic, antiacne, antineoplastic | [Uses]
Lornoxicam belongs to the oxicam class. It has anti-inflammatory and antipyretic properties. Lornoxicam prevents the synthesis of prostaglandin (PG) by inhibiting cyclo-oxygenase. It is used to relieve various types of symptoms associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute sciatica and low back pain.Lornoxicam is approved for use in Japan.
Lornoxicam has been used as a drug in melanin binding study with cassette dosing and rapid equilibrium dialysis inserts. Lornoxicam differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug. | [Definition]
ChEBI: A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 6-chloro-4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for th
treatment of pain, primarily resulting from inflammatory diseases of the joints, osteoarthritis, surgery, sciatica and other inflammations. | [Indications]
Lornoxicam is a non-steroidal anti-inflammatory drug (NSAID) that is used as a painkiller (analgesic). A high level of pain relief is experienced by about 45% of those with moderate to severe postoperative dental pain after a single dose of lornoxicam 8 mg, compared to about 10% with placebo. This is comparable to the proportion experiencing the same level of pain relief with ibuprofen 200 to 400 mg. Adverse events were generally mild and did not differ from placebo in these singe dose studies. There were insufficient data to assess duration of action, but it is likely to be similar to ibuprofen 200 mg. | [Brand name]
Xefo | [in vitro]
studies on intact human cells showed that lornoxicam intensively inhibit cox-1 and cox-2 with the lowest ic50 among a large panel of nsaids tested. similar findings were obtained in the whole blood for cox-1/-2. in addition lornoxicam suppressed no formation in a dose-dependently manner with an ic50 of 65 μm. [2] | [in vivo]
in vivo studies found that lornoxicam was as effective as comparative nsaids and that 8 mg lornoxicam was more effective than 10 mg morphine as a pain-reliever after oral surgery. orally administration of lornoxicam at 16-24 mg daily was more effective than tramadol at 300 mg daily in pain-alleviating after knee surgery. compared to naproxen, lornoxicam showed higher therapeutic potency and lower gastrointestinal toxicity. this was probably due to the short half-life of lornoxicam as compared to the other oxicams. [3] | [IC 50]
a potent cox-1 and cox-2 inhibitor with ic50 values of 5 nm and 8 nm, respectively. |
|
|